Two high-priced drugs for spinal muscular atrophy called not cost effective - STAT

Two high-priced drugs for spinal muscular atrophy called not cost effective - STAT

STAT Plus: Two high-priced drugs for spinal muscular atrophy are not cost effective, analysis concludes

By ED SILVERMAN

SCOTT LAPIERRE/BOSTON GLOBE

"As far as the value of money is concerned, these are very expensive.” said Dr. David Rind of the Institute for Clinical and Economic Review.

READ MORE